Olympus and Canon have launched the Aplio i800 EUS system in the U.S., aiming to improve visualization in complex hepatobiliary and pancreatic conditions—areas where diagnosis remains challenging. The system combines high-resolution imaging with workflow features like automated gain and full-focus imaging, designed to support more consistent and efficient procedures. The signal: As EUS adoption grows, vendors are competing less on access—and more on image quality and procedural efficiency.
Author: Abhay Panchal
United Digestive (UD), one of the largest physician practice management companies supporting gastrointestinal providers and partner practices throughout the Southeast, is driving significant organic growth through strategic investments in new clinics and endoscopy centers, the recruitment of top physician and advanced practice provider talent across its network, and the implementation of new ancillaries to expand its comprehensive care model. Together, these efforts are improving access, reducing wait times, and bringing high-quality GI care closer to patients across UD’s network. “Organic growth has always been a core pillar of our organization’s strategic initiatives” said Neal C. Patel, MD, CEO of United…
GLP-1 receptor agonists are rapidly evolving from diabetes and weight-loss drugs into broader cardiometabolic therapies, with emerging anti-inflammatory and potential neuroprotective benefits. But their expansion comes with a clear clinical constraint: gastrointestinal tolerability. From nausea and delayed gastric emptying to higher discontinuation rates, GI side effects remain the primary barrier to sustained use—shaping both patient adherence and procedural considerations in practice. The shift is clear: GLP-1s are no longer niche therapies—but managing their GI impact is becoming central to their real-world success.
Medical gaslighting, defined as the dismissal or minimization of patient-reported symptoms in the absence of adequate justification, has emerged as a relevant yet insufficiently examined phenomenon in gastroenterology. Patients with gastrointestinal disorders are particularly vulnerable due to the prevalence of conditions that rely on subjective symptom reporting, evolving diagnostic criteria, and limited availability of definitive biomarkers, especially among functional gastrointestinal disorders and disorders of gut-brain interaction as defined by the Rome IV criteria.
A new ranking of America’s most innovative companies highlights a broad shift in how innovation is defined in healthcare—spanning not just new products, but processes and culture. From pharma giants to health systems and AI startups, 53 healthcare organizations made the list, reflecting innovation across the entire care continuum. What stands out is that innovation is no longer limited to breakthrough therapies. It now includes digital transformation, operational efficiency, and the ability to embed innovation into organizational culture. The implication is clear: In healthcare, innovation is becoming less about isolated breakthroughs—and more about system-wide capability.
Delayed resumption of direct oral anticoagulants following outpatient colonoscopy was associated with higher thromboembolic risk without a reduction in gastrointestinal (GI) bleeding, according to a cohort study published in Clinical Gastroenterology and Hepatology. Management of anticoagulation around colonoscopy remains a common clinical challenge. Temporary interruption reduces post-procedural bleeding risk, but prolonged interruption may increase the risk of stroke and other thromboembolic events, noted Lawrence Jun Leung, MD, MPH, and colleagues. “Currently, little is known about the optimal timing for DOAC resumption after colonoscopy to minimize the risks of both gastrointestinal bleeding and thromboembolic events, and the lack of an evidence…
At the 2026 Gut Microbiota for Health World Summit, one theme stood out clearly: despite increasingly sophisticated tools like AI, metabolomics, and sequencing, the foundations of gut health remain remarkably simple. Across sessions, researchers repeatedly emphasized that dietary patterns—not supplements, testing, or personalization—continue to drive the most meaningful changes in the microbiome. The Mediterranean diet, in particular, remains one of the most consistently validated approaches, associated with greater microbial diversity, improved metabolite production, and reduced inflammation. What’s evolving is not the core advice, but the depth of understanding. Concepts like the “plant food matrix” and microbial metabolites are helping explain…
Guidance alerting endoscopists to adjust their peripheral gaze significantly improved adenoma detection in colonoscopies — particularly for flat lesions — regardless of the endoscopist’s experience level and without increasing procedure time, according to a recent study in Clinical Gastroenterology and Hepatology. The study was led by Fumiaki Ishibashi, PhD, with the Department of Gastroenterology at the International University of Health and Welfare Ichikawa Hospital in Chiba, Japan. In the study, a real-time eye-tracking system monitored endoscopists’ gaze and prompted them to look at the peripheral area.
The chief executive of America’s largest public hospital system says he is prepared to start replacing radiologists with artificial intelligence in some circumstances, once the regulatory landscape catches up. Mitchell H. Katz, MD, president and CEO of NYC Health + Hospitals, recently spoke during a panel discussion held by Crain’s New York Business. The trained internal medicine specialist noted how AI is increasingly being used to interpret mammograms and X-rays. This presents an opportunity to save on how much hospitals spend on radiologists, who have become more costly amid rising demand for imaging, Crain’s reported Thursday. “We could replace a…
One of the most persistent breakdowns in healthcare isn’t diagnosis—it’s execution. Even when clinicians make the right treatment decision, delays in prescriptions, prior authorizations, and affordability often prevent patients from getting timely care. A new partnership between OpenEvidence and Tandem is targeting exactly this gap—connecting evidence-based clinical decision-making directly to automated prescription fulfillment and prior authorization workflows. OpenEvidence brings real-time, AI-powered clinical guidance used in over a million consultations daily, while Tandem automates the downstream process—handling prior authorizations, appeals, pharmacy routing, and cost support. The result is a shift from fragmented steps to a continuous, end-to-end care pathway. This matters…